News

1 to 9 of 92 results

Hospira launches first biosimilar MAb Inflectra (infliximab) in major European markets

Hospira launches first biosimilar MAb Inflectra (infliximab) in major European markets

16-02-2015

US injectable generics and biosimilars major Hospira says it has launched the first biosimilar monoclonal…

Anti-Arthritics/RheumaticsBiosimilarsCellTrionEuropeGenericsHospiraInflammatory diseasesInflectraJohnson & JohnsonMarkets & MarketingMerck & CoRemicadeRemsima

New drugs and biosimilars to drive rheumatoid arthritis to $19.3 billion by 2023

New drugs and biosimilars to drive rheumatoid arthritis to $19.3 billion by 2023

13-01-2015

The launch of novel drugs and biosimilars will drive steady growth in the global rheumatoid arthritis…

AmgenAnti-Arthritics/RheumaticsEnbrelHumiraMarkets & MarketingPharmaceuticalResearchUSA

Hikma to launch colchicine in USA as Takeda’s injunction fails

13-01-2015

Jordon-headquartered Hikma Pharmaceuticals saw its shares rise 4.2% to a record high of £23.80, after…

Anti-Arthritics/RheumaticsColchicineColcrysGenericsHikma PharmaceuticalsLegalMarkets & MarketingMitigareTakeda PharmaceuticalUSA

Torrent enters exclusive licensing deal with Reliance Life Sciences for three biosimilars

Torrent enters exclusive licensing deal with Reliance Life Sciences for three biosimilars

29-12-2014

Ahmedabad, India-based Torrent Pharmaceuticals last week entered into an exclusive licensing agreement…

adalimumabAnti-Arthritics/RheumaticsBiosimilarscetuximabGenericsIndiaLicensingMarkets & MarketingOncologyrituximabTorrent Pharmaceuticals

Teva, Actavis and Mylan launch generic Celebrex capsules in USA

Teva, Actavis and Mylan launch generic Celebrex capsules in USA

10-12-2014

Israel-based generics giant Teva Pharmaceutical Industries said today that it has launched the first…

ActavisAnti-Arthritics/RheumaticsCelebrexGenericsMarkets & MarketingMylanPfizerTeva Pharmaceutcal IndustriesUSA

Zydus launches world’s first biosimilar of Humira

Zydus launches world’s first biosimilar of Humira

09-12-2014

A biosimilar of AbbVie’s blockbuster drug Humira (adalimumab) has been launched in India by generic…

AbbVieAnti-Arthritics/RheumaticsBiosimilarsHumiraIndiaMarkets & MarketingZydus Cadila

Nippon Kayaku launches biosimilar Remicade in Japan

Nippon Kayaku launches biosimilar Remicade in Japan

01-12-2014

Japanese drugmaker Nippon Kayaku has launched the sale of Infliximab BS for IV Infusion 100mg, a biosimilar…

Anti-Arthritics/RheumaticsBiosimilarsGenericsinfliximabJapanJohnson & JohnsonMarkets & MarketingNippon KayakuRemicade

Rheumatoid arthritis drug market will grow to $18.2 billion in 2023, report

17-09-2014

The rheumatoid arthritis (RA) disease-modifying antirheumatic drug market will increase from $14 billion…

Anti-Arthritics/RheumaticsbaricitinibBiosimilarsEli LillyEuropeIncyteJapanMarkets & MarketingPfizerPharmaceuticalUSAVertexXeljanz

1 to 9 of 92 results

COMPANY SPOTLIGHT

Menarini

Back to top